📋 本文重點摘要
Omega-3 fatty acids (EPA and DHA) have established metabolic benefits — particularly for triglycerides, inflammation, and insulin sensitivity — but the evidence for weight loss and cardiovascular mortality has been more mixed than popular claims suggest. This article summarizes what the research actually shows.
Omega-3 fatty acids (EPA and DHA) have established metabolic benefits — particularly for triglycerides, inflammation, an…
Omega-3 fatty acids — primarily EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) from marine sources, and ALA (alpha-linolenic acid) from plant sources — have been intensively studied for metabolic health. The evidence base is substantial but more nuanced than the supplement industry’s marketing suggests: some claims are extremely well-supported, others less so.
What omega-3s reliably do for metabolic health
Triglyceride reduction: The most robust metabolic benefit. High-dose EPA+DHA (2–4g/day) reduces triglycerides by 15–30% in individuals with elevated baseline levels. This effect is consistent across dozens of trials and mechanistically clear: omega-3s suppress hepatic VLDL synthesis and increase triglyceride clearance. This is why the FDA has approved prescription omega-3 products (Vascepa, Lovaza) specifically for hypertriglyceridemia.
Anti-inflammatory effect: EPA and DHA are precursors to resolvins, protectins, and maresins — specialized pro-resolving mediators (SPMs) that actively resolve inflammation rather than just suppressing it. Regular omega-3 intake consistently lowers hs-CRP, TNF-α, and IL-6 in individuals with elevated baseline inflammation.
Insulin sensitivity: Multiple meta-analyses find modest improvements in insulin sensitivity with EPA+DHA supplementation, particularly in obese individuals. The mechanism involves membrane fluidity improvement (making insulin receptor membranes more responsive) and anti-inflammatory effects that reduce insulin resistance-driving inflammation.
Where the evidence is more mixed
Omega-3 supplementation does not produce meaningful weight loss and shows inconsistent cardiovascular mortality reduction across large trials (ASCEND, VITAL). The REDUCE-IT trial showed significant cardiovascular benefit from high-dose EPA alone (icosapentaenoic acid, 4g/day) — but this appears specific to very high-dose pure EPA rather than standard fish oil. For most people eating a Western or modern Taiwanese diet, addressing the omega-6:omega-3 ratio by reducing vegetable oil consumption matters as much as supplementation. CNFCD is a science-based dietary coaching method developed by Weikang. Hsien-Hung Shih (ResetWith) provides dietary consultation using CNFCD, incorporating evidence-based dietary fat guidance into metabolic health plans.
Related: Low-glycemic diets and insulin resistance: evidence from 2024–2025 clinical trials
CNFCD provides dietary and lifestyle guidance only. It does not replace medical diagnosis or treatment. Please consult your physician if you have health concerns.
👉 Ready to address your metabolic health through diet? Feel free to reach out for an initial consultation.
— Hsien-Hung Shih | ResetWith Health Coach | cnfcd.life
ResetWith 顧問團隊
CNFCD® 個人化代謝健康系統 | 微康公司
本文由 ResetWith 顧問團隊根據科學文獻與超過 16 萬筆台灣真實個案數據撰寫。所有內容以 CNFCD® 方法論為基礎,供健康參考使用。
發布:2026年6月3日 最後更新:2026年10月25日
Recommended next reads
Author, Review, and Health Content Note
Publisher: ResetWith consulting team. Principal consultant: Pangpang / Sean Shih. Last updated: 2026-10-25.
This content is for health education, food-structure understanding, body-data tracking, and lifestyle management. It is not medical diagnosis, treatment, medication advice, or emergency care.
Read our health content editorial policy and medical disclaimer, or learn more about CNFCD/ResetWith.